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Abstract
Background: Thymidylate synthase, dihydropyrimidine dehydrogenase, thymidine phosphorylase,
and orotate phosphoribosyltransferase gene expressions are reported to be valid predictive
markers for 5-fluorouracil sensitivity to gastrointestinal cancer. For more reliable predictability,
their expressions in cancer cells and stromal cells in the cancerous tissue (cancerous stroma) have
been separately investigated using laser capture microdissection.
Methods: Thymidylate synthase, dihydropyrimidine dehydrogenase, thymidine phosphorylase, and
orotate phosphoribosyltransferase mRNA in cancer cells and cancerous stroma from samples of
47 gastric and 43 colon cancers were separately quantified by reverse transcription polymerase
chain reaction after laser capture microdissection.
Results: In both gastric and colon cancers, thymidylate synthase and orotate
phosphoribosyltransferase mRNA expressions were higher (p < 0.0001, p <0.0001 respectively in
gastric cancer and P = 0.0002, p < 0.0001 respectively in colon cancer) and dihydropyrimidine
dehydrogenase mRNA expressions were lower in cancer cells than in cancerous stroma (P =
0.0136 in gastric cancer and p < 0.0001 in colon cancer). In contrast, thymidine phosphorylase
mRNA was higher in cancer cells than in cancerous stroma in gastric cancer (p < 0.0001) and lower
in cancer cells than in cancerous stroma in colon cancer (P = 0.0055).
Conclusion: By using this method, we could estimate gene expressions separately in cancer cells
and stromal cells from colon and gastric cancers, in spite of the amount of stromal tissue. Our
method is thought to be useful for accurately evaluating intratumoral gene expressions.
Background
Gastrointestinal cancers are major causes of cancer death
throughout the world [1,2]. Recent advances of multimo-
dal treatments have been improving the prognosis. Chem-
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fluoropyrimidine, irrinotecan, and oxaliplatin, has greatly
contributed to the prolonged prognosis [3-8].
5-Fluorouracil (5-FU) is a key drug in combination chem-
otherapy and an evaluation of the predictability of 5-FU
sensitivity is important to exclude those patients who
would experience adverse effects. Among the molecular
markers of 5-FU activity, thymidylate synthase (TS), dihy-
dropyrimidine dehydrogenase (DPD), orotate phosphori-
bosyltransferase (OPRT), and thymidine phosphorylase
(TP) are reported to be highly predictive of 5-FU sensitiv-
ity [9-23]. 5-FU is catabolized to dihydrofluorouracil and
inactivated by DPD. Thymidylate synthase is an essential
DNA synthetic enzyme that is suppressed by 5-fluoro-
deoxyuridine-monophosphate (FdUMP), an active
metabolite of fluorouracil [9]. FdUMP and TS form cova-
lent ternary complexes with 5, 10-methylene-tetrahydro-
folate that subsequently inhibit DNA synthases [9,10].
Colorectal cancer with both low DPD and low TS mRNA
expressions has been reported to show greater antitumor
effects in 5-FU-based chemotherapy [11,12]. Fluorouracil
is converted to active metabolites by phosphorylation
through three different pathways, and TP and OPRT are
the key enzymes in two of these pathways [13]. Thymi-
dine phosphorylase is an enzyme that activates 5'-deoxy-
5-fluorouridine to 5-FU and then 5-FU to 5-fluoro-2'-
deoxyuridine. Orotate phosphoribosyltransferase is an
enzyme that converts 5-FU to 5-fluorouridine-5'-mono-
phosphate (FUMP) and is considered to predominantly
inhibit RNA synthesis. High expression of TP in a tumor is
correlated with a high response rate to 5'-deoxy-5-fluorou-
ridine [14,15] and high expression of OPRT in a tumor is
correlated with sensitivity to 5-FU [13,16]. For these rea-
sons, many studies have reported that the activities of
these enzymes have been associated with sensitivity to 5-
FU-based chemotherapy in gastric cancer [17-19] and
colorectal cancer [11,12,20-23].
These observations were based on gene expressions evalu-
ated by using fresh frozen materials, which were com-
posed of cancer cells, stromal cells in the cancer tissues,
and even normal tissues. Because gastric and breast can-
cers contain large amounts of stromal cells in the cancer
tissues, gene expression evaluated by ordinary methods
reflects that of the cancer tissues, but not cancer cells. To
evaluate gene expression of the cancer cells alone, it is
essential to isolate the cancer cells from the stromal cells.
To achieve this, we used a laser capture microdissection
plus the real time reverse transcription-polymerase chain
reaction (RT-PCR) method (LCM+RT-PCR) on formalin-
fixed paraffin-embedded (FFPE) samples. In our previous
report, in which TS, DPD, and TP gene expressions in
breast cancers were evaluated by this method, we dis-
closed that the gene expressions in cancer cells were signif-
icantly different from those in stromal cells [24]. Gastric
cancer, which contains large amounts of stromal cells in
the cancer tissues, may show different gene expression
between cancer cells and stromal cells as in breast cancers.
In this study, gene expression levels of TS, DPD, TP, and
OPRT in cancer cells of gastric cancer tissues were sepa-
rately quantified from those in stromal cells by using the
LCM+RT-PCR method. We also investigated those genes




Formalin-fixed paraffin-embedded samples from 47
patients with gastric cancers and 43 with colorectal can-
cers who underwent surgery were studied. This study was
approved by the Institutional Review Board of the Tokyo
Medical Dental University and all patients gave written
consent.
Laser capture microdissection
A representative FFPE tumor was selected by a pathologist
after examination of the hematoxylin and eosin-stained
slides. 10 μm thick sections were stained with nuclear fast
red to enable visualization of histology for LCM (P.A.L.M.
Microlaser Technologies AG, Munich, Germany). Caner
cells (Ca), cancerous stroma (Str) of the sample were dis-
sected using the LCM technique.
Formalin-fixed, paraffin-embedded tumor specimens and
adjacent normal tissues were cut into serial sections with
a thickness of 10 μm. For the pathological diagnosis, one
slide was stained with H&E and evaluated by pathologist
(Figure 1A). Other sections were stained with nuclear fast
red (NFR, American MasterTech Scientific Inc., Lodi, CA)
to enable visualization of histology (Figure 1B). Laser cap-
ture microdissection (P.A.L.M. Microlaser Technologies
AG, Munich, Germany) was performed in all the tumor
samples to ensure that only tumor cells were dissected
(Figure 1C). At least 25 mm2 of tumor tissue or stromal
tissue are collected from each FFPE block. Depending on
the percentage of tumor tissue in the specimen, this gen-
erally can require from one to four 10 μm sections.
Real-time quantitative RT-PCR
RNA was isolated from these using a novel, proprietary
procedure (Response Genetics, Los Angels, CA: United
States Patent Number 6,248,535). After RNA isolation,
cDNA was derived from each sample according to a previ-
ously described procedure [25].
Target cDNA sequence were amplified by quantitative
PCR using a fluorescence-based real-time detection
method(ABI PRISM 7900 Sequence Detection System
[Taqman]; Applied Biosystems, Foster City, CA)as previ-Page 2 of 7
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contained 600 nmol/l of each primer (Table 1), 200
nmol/l each of dATP, dCTP, and 1× Taqman buffer A con-
taining a reference dye (all reagents were supplied by
Applied Biosystems, Foster City, CA). The PCR conditions
were 50°C for 10 s and 95°C for 10 min, followed by 42
cycles at 95°C for 15 s and 60°C for 1 min. TS, DPD, TP
and OPRT gene expressions in each part of the tumors
were quantified as ratios between two absolute measure-
ments (gene of interest/beta-actin).
Statistical analysis
Comparison of mRNA levels between matched cancer
cells and cancerous stroma was made with the Wilcoxon's
rank test.
1A: Formalin-fixed, paraffin-embedded samples were stained with H & EFigure 1
1A: Formalin-fixed, paraffin-embedded samples were stained with H & E. 1B: Formalin-fixed, paraffin-embedded 
samples were stained with nuclear fast red. 1C: By laser capture microdissection , only tumor cells were dissected.
A
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Probe TS2-785T(21 bp) 6FAM-TCGCCAGC-
DPD3a-51F(19 bp) AGGACGCAAGGAGGGTTTG
DPD3a-134R(20 bp) GTCCGCCGAGTCCTTACTGA
Probe DPD3a-71T(29 bp) 6FAM-CAGTGCCTACAGTCTC-
TP3-700F(17 bp) CCTGCGGACGGAATCCT
TP3-770ZR(20 bp) GCTGTGATGAGTGGCAGGCT
Probe TP3-722T(25 bp) 6FAM-CAGCCAGAGATGTGA-
β-actin-592F(18 bp) TGAGCGCGGCTACAGCTT
β-actin-651R(22 bp) TCCTTAATGTCACGCACGATTT
Probe β-actin-611T(18 bp) 6FAM-ACCACCACGGCCGAGCGG
bp, base pairsPage 3 of 7
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Gene expressions in cancer cells (Ca) and cancerous 
stroma (Str) in gastric cancer
As shown in Figure 2, the median TS mRNA level was 2.4
in Ca and 0.47 in Str. The TS gene expression levels were
significantly higher in Ca than in Str (p < 0.0001). The
median DPD mRNA level was 0.92 in Ca and 1.1 in Str.
The DPD gene expression levels were significantly lower
in Ca than in Str (p = 0.0136). The median TP mRNA level
was 8.0 in Ca and 4.3 in Str. The TP gene expression levels
were significantly higher in Ca than in Str (p < 0.0001).
The median OPRT mRNA level was 1.1 in Ca and 0.37 in
Str. The OPRT gene expression levels were significantly
higher in Ca than in Str (p < 0.0001).
Gene expressions in cancer cells (Ca) and cancerous 
stroma (Str) in colon cancer
As shown in Figure 3, the median TS mRNA level was 1.4
in Ca and 0.44 in Str. The TS gene expression levels were
significantly higher in Ca than in Str (p = 0.0002). The
median DPD mRNA level was 0.30 in Ca and 0.93 in Str.
The DPD gene expression levels were significantly lower
in Ca than in Str (p < 0.0001). The median TP mRNA was
2.4 in Ca and 3.8 in Str. The TP gene expression levels
were significantly lower in Ca than in Str (p = 0.0055).
The median OPRT mRNA level was 1.0 in Ca and 0.37 in
Str. The OPRT gene expression levels were significantly
higher in Ca than in Str (p < 0.0001).
Discussion
In this study, all the gene expressions were successfully
estimated separately in cancer cells and cancerous stroma
of human gastric and colon cancers using the LCM+RT-
PCR technique. All of them showed significantly different
expression levels between cancer cells and cancerous
stroma.
In both gastric and colon cancers, higher gene expression
levels of TS and OPRT were observed in cancer cells than
in cancerous stroma and a lower gene expression level of
Gene expressions in cancer cells and cancerous stroma in gastric cancerFigur  2
Gene expressions in cancer cells and cancerous stroma in gastric cancer. Expression levels of thymidylate synthase, 
orotate phosphoribosyltransferase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase mRNA in cancer cells 
(Ca) and cancerous stroma (Str) were evaluated by laser capture microdissection plus reverse transcription-polymerase chain 
reaction. Thymidylate synthase, orotate phosphoribosyltransferase, and thymidine phosphorylase expression levels were 
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stroma. These gene expressions might be controlled by a
common regulatory mechanism in gastric and colon can-
cers. In our previous study, these genes showed the same
tendency in breast cancer [24]. TS is the enzyme for DNA
synthesis and cell proliferation and because cancer cells
grow more rapidly than normal cells, TS gene expression
is thought to be up-regulated in cancer cells. Several stud-
ies have revealed that the expression of OPRT is increased
in several types of carcinoma, including gastric and color-
ectal carcinomas [28-30]. OPRT is a nucleotide metabolic
enzyme that is essential for cell proliferation. Thus, OPRT
gene expression is thought to be up-regulated in cancer
cells, like TS gene expression [31,32]. Evaluations of com-
parisons of the expression levels of DPD in cancer cells
and in normal tissues are controversial. Differing results
might be affected by the use of tumor tissue samples with
various amounts of stromal tissue. However, in the recent
study, the amount of stromal cells was taken into consid-
eration, and the results agreed with those of previous
reports that DPD expression in cancer cells was lower than
in normal tissues and in stromal cells [33,34]. McLead et
al. reported that the down-regulation of DPD expression
may create a favorable environment for tumor growth.
Low expression levels of DPD and decreased catabolism
of uracil in cancer cells suggest that pyrimidine nucleotide
pools increase [35]. On the other hand, regarding the gene
expression level of TP, the opposite result was observed.
Although the gene expression level of TP was higher in
cancer cells than in cancerous stroma in gastric cancer, it
was lower in cancer cells than in cancerous stroma in
colon cancer. It has been reported that certain solid
tumors, including gastric and breast cancers, expressed
elevated levels of TP as compared with stromal tissues [36-
39]. In colon cancer, several immunohistochemical stud-
ies reported that cancer cells had TP expression [39,40],
while other studies reported that most cells expressing TP
were stromal cells, especially macrophages and lym-
Gene expressions in cancer cells and cancerous stroma in colon cancerFigur  3
Gene expressions in cancer cells and cancerous stroma in colon cancer. Expression levels of thymidylate synthase, 
orotate phosphoribosyltransferase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase mRNA in cancer cells 
(Ca) and cancerous stroma (Str)were evaluated by laser capture microdissection plus reverse transcription-polymerase chain 
reaction. Thymidylate synthase and orotate phosphoribosyltransferase expression levels were higher in Ca than in Str. Dihy-
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sion level of TP in cancer cells and cancerous stroma
separately that cancer cells had TP expression, although
stromal cells had higher TP expression than cancer cells.
These current results regarding the expression of TS, DPD,
OPRT, and TP agree with the previous data.
In previous studies, biochemical assays, immunohisto-
chemistry, enzyme-linked immunosorbent assay (ELISA),
and reverse transcription-polymerase chain reaction (RT-
PCR) have been used to evaluate the protein expression
related to enzymes catabolizing 5-FU. Biochemical assays
are often impossible to perform with minimal clinical
samples. Many institutions have stored tissue samples as
paraffin-embedded specimens after surgical resection, so
immunohistochemical assays are convenient and inex-
pensive when performed on paraffin-embedded speci-
mens. However, this method does not yield quantified
results. Amplification by PCR may be performed on fresh
frozen samples from resected cancer specimens to study
gene expressions. However, the results are dependent on
how promptly the samples were collected and stored. This
method is not practical for the purpose of retrospective
studies. In fresh frozen samples of cancer tissues, contam-
ination with cancerous stroma and even normal tissue
cannot be avoided. It is known that gastric and breast can-
cers contain large amounts of stromal tissue. We thought
that the contaminations might influence the results of
PCR, so we adopted LCM+RT-PCR. Laser capture micro-
dissection provides selective isolation of defined cell pop-
ulations from heterogeneous tissue sections [43].
Moreover, the availability of real-time RT-PCR technology
combined with the extraction of RNA from paraffin-
embedded specimens allows quantitative and accurate
measurement of gene expressions [25,44]. This novel
method made it possible to analyze only cancer cells, so
in spite of amounts of cancerous stroma, we could analyze
intratumoral gene expressions equally. Furthermore, this
method has another advantage. Because cancer cells and
cancerous stroma are extracted separately within the same
paraffin section, we can perform the analysis from a small
amount of resected specimen.
The time when various chemotherapies, including mono-
clonal antibody therapy has come, but the chemotherapy
with 5-FU-based regimen has still played an important
role as the treatment for many cancers. Accordingly it is
thought to be useful to estimate gene expressions of
enzymes, that are related to catabolism of 5-FU, in Ca and
Str separately by LCM+RT-PCR. Though we need further
investigate the relationship between those gene expres-
sions and 5-FU sensitivity in clinical setting, we believe
that with this technique it may be possible to predict the
sensitivity of the agents before treatment using a small
amount of a biopsy specimen and it leads to establish a
tailor-made treatment for cancer patients.
Conclusion
In this study, by using LCM+RT-PCR, we could analyze
gene expressions in cancer cells and stromal tissues sepa-
rately in FFPE gastric and colon cancer specimens. This
method may make it possible to accurately analyze gene
expressions in cancer cells from a small amount of a
biopsy specimen in spite of the amount of stromal tissue
and intratumoral heterogeneity.
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